Other institutions

Gavi, the Vaccine Alliance

Vaccinations are among the most effective healthcare measures. Yet, despite this fact, by the start of our millennium, some 30 million girls and boys had not been fully immunised. While children in industrialised countries receive an average of eleven to twelve vaccinations, children of the same age in developing countries only receive an average of five to six vaccinations. Newly developed, expensive vaccines – such as the one against Hepatitis B – are generally not available to the world's poorest children.

It was because of this, and the stagnating vaccination rates in the 1990s, that the "Global Alliance for Vaccines and Immunization, Gavi" was formed in the year 2000.

Public-private partnership

Gavi, the Vaccine Alliance is a public-private partnership whose task it is to help save the lives of children in developing countries and emerging economies by providing easy access to immunisations and by improving health systems. The Vaccine Alliance aims to achieve this by supporting national immunisation programmes, introducing new vaccines and facilitating additional financing options. Being one of the world's largest buyers of vaccines worldwide, the Vaccine Alliance is in a position to negotiate prices with pharmaceutical companies, thus helping to constantly lower the cost of vaccines. This should enable countries receiving support from Gavi to maintain high immunisation rates even without international assistance and to ensure equal access to life-saving vaccines.

All key decision-makers in the field of vaccines work together as partners within the Alliance. These key decision-makers include the governments of industrialised and developing countries, the WHO, UNICEF, the World Bank, the Bill and Melinda Gates Foundation, manufacturers of vaccines from industrialised countries and emerging economies, as well as public health bodies and non-governmental organisations.

The Gavi Alliance is based in Geneva and, since early 2009, has been registered there as a foundation in accordance with Swiss law.

Strategy up to 2020

Gavi's strategy for the period from 2016 to 2020 has four objectives:

  1. Accelerate equitable uptake and coverage of vaccines;
  2. Increase effectiveness and efficiency of immunisation delivery as an integrated part of strengthened health systems;
  3. Improve sustainability of national immunisation programmes;
  4. Shape markets for vaccines and other immunisation products.

To date, nearly 640 million children have been immunised with support from Gavi. The aim of the current strategy is to immunise a further 300 million children in developing countries with the most important vaccines by the year 2020. It is estimated that, in the long term, this will save five to six million lives.

Avoiding life-threatening diseases

Gavi, the Vaccine Alliance, supports the use of 13 different vaccines – for example against Hepatitis B, Haemophilus influenza B (which can cause meningitis and pneumonia), tetanus, whooping cough, measles, polio and diphtheria.

In addition, Gavi provides support for vaccination campaigns against pneumococcal infections and rotaviruses. Pneumococci are the main cause of pneumonia, and rotaviruses cause severe diarrhoeal diseases. Pneumonia and diarrhoeal diseases are the main causes of child mortality in developing countries.

Successful interventions

The interventions launched by Gavi in collaboration with its partners are playing their part in helping to realise Goal no. 3 of the 2030 Agenda for Sustainable Development: good health and well-being for all. According to figures published by the Alliance, the immunisation programmes and vaccination campaigns supported so far have helped to prevent more than nine million future deaths in developing countries.

There has been a significant increase in immunisation coverage in poor countries, and the number of children who have not been fully immunised has fallen to 19.5 million. In many developing countries, vaccines are now available at a fraction of the cost incurred in industrialised countries. Nowadays, newly developed vaccines are available almost simultaneously in industrialised and developing countries. Sixteen Gavi-supported countries are now in a position to finance their immunisation programmes entirely on their own.

What Germany is doing

The BMZ has been supporting Gavi, the Vaccine Alliance since 2006. When Germany hosted the replenishment conference held in January 2015, it significantly increased its contribution to Gavi. Between 2016 and 2020, Germany will make available a total of 600 million euros for the Alliance's work. This makes Germany the fourth largest donor to the Vaccine Alliance. In total, Gavi was able to mobilise more than 7.5 billion US dollars at the 2015 replenishment conference.

Together with France, the European Commission, Ireland and Luxembourg, Germany makes up one of the donor voting constituencies in the Alliance. In 2018, Germany will act as Deputy Representative Member and, in 2019, as Representative Member of its voting constituency on Gavi's Board.

More information


See also

External Link


Gavi, the Vaccine Alliance
2 Chemin des Mines
1202 Geneva
Phone: +41 / 22 / 9 09 65 00
Fax: +41 / 22 / 9 09 65 50

BMZ glossary

Close window


Share page